A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease.

Noor NA, Mohammed HS, Mourad IM, Khadrawy YA, Aboul Ezz HS

Life sciences17 May 2016Cited by 20 (Europe PMC)

PMID27210889DOI10.1016/j.lfs.2016.05.022PepBankPUB-27210889

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In Parkinsonian rats, Cerebrolysin restored midbrain dopamine levels.
In plain wordsIn Parkinsonian rats, Cerebrolysin restored midbrain dopamine levels compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
IncreaseMidbrain dopamine
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
Treatment of Parkinsonian animals with CBL succeeded in restoring the midbrain and striatum dopamine levels.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088901
02AnimalAnimal study (in vivo)Mechanism
In Parkinsonian rats, Cerebrolysin restored striatum dopamine levels.
In plain wordsIn Parkinsonian rats, Cerebrolysin restored striatum dopamine levels compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
IncreaseStriatum dopamine
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
Treatment of Parkinsonian animals with CBL succeeded in restoring the midbrain and striatum dopamine levels.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088902
03AnimalAnimal study (in vivo)Mechanism
In Parkinsonian rats, Cerebrolysin normalized increased MDA levels.
In plain wordsIn Parkinsonian rats, Cerebrolysin reduced elevated MDA levels compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
DecreaseMDA levels
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
In addition, it normalized the increased MDA and NO levels recorded in the Parkinsonian animals and replenished the decreased level of midbrain GSH.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088903
04AnimalAnimal study (in vivo)Mechanism
In Parkinsonian rats, Cerebrolysin normalized increased NO levels.
In plain wordsIn Parkinsonian rats, Cerebrolysin reduced elevated NO levels compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
DecreaseNO levels
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
In addition, it normalized the increased MDA and NO levels recorded in the Parkinsonian animals and replenished the decreased level of midbrain GSH.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088904
05AnimalAnimal study (in vivo)Mechanism
In Parkinsonian rats, Cerebrolysin replenished decreased midbrain GSH levels.
In plain wordsIn Parkinsonian rats, Cerebrolysin restored midbrain GSH levels compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
IncreaseMidbrain GSH
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Oxidative stress · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
In addition, it normalized the increased MDA and NO levels recorded in the Parkinsonian animals and replenished the decreased level of midbrain GSH.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088905
06AnimalAnimal study (in vivo)Efficacy outcome
In Parkinsonian rats, Cerebrolysin improved behavioral aspects alongside biochemical recovery.
In plain wordsIn Parkinsonian rats, Cerebrolysin improved behavior compared with the Parkinsonian model group.
Peptide
Cerebrolysin
Outcome
IncreaseBehavioral aspects
Study
ratn: not reported in source
6-OHDA-lesioned Parkinsonian rats
Comparator
Parkinsonian model group
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
2.5ml/kg · intraperitoneal · 21daysAs given in this study (rat).
Source sentences
Summary
In addition to the recorded recovery of the biochemical parameters, there was a parallel improvement in the animal's behavioral aspects.
1 context sentence(design, population, supporting numbers)
Summary · context
CBL-treated group which received a daily intraperitoneal administration of CBL (2.5ml/kg) initiated 24h after induction of Parkinsonism for 21days.
Report a problemFND-2721088906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.